Advertisement

This Is the Best News Yet for Moderna's COVID Vaccine

This Is the Best News Yet for Moderna's COVID Vaccine

Moderna (NASDAQ: MRNA) has announced its share of good news in the past couple of months. The biotech company generated positive results in the phase 3 trial of its investigational coronavirus vaccine. Moderna also has signed advance purchase agreements for 2021 that represent more than $11 billion in revenue.